Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with hormone responsive advanced breast cancer: no evidence of a pharmacokinetic interaction between exemestane and fulvestrant.

被引：0
|
作者：
Mrozek, E. [1 ]
Schaaf, L. J. [1 ]
Ramaswamy, B. [1 ]
Shiels, D. [1 ]
Houton, L. [1 ]
Shapiro, C. L. [1 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：387S / 387S
页数：1
相关论文
共 50 条
  • [1] Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer
    Mrozek, Ewa
    Layman, Rachel
    Ramaswamy, Bhuvaneswari
    Schaaf, Larry
    Li, Xiaobai
    Ottman, Susan
    Shapiro, Charles L.
    [J]. CLINICAL BREAST CANCER, 2012, 12 (02) : 151 - 156
  • [2] Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
    Robertson, John F. R.
    Ferrero, Jean-Marc
    Bourgeois, Hugues
    Kennecke, Hagen
    de Boer, Richard H.
    Jacot, William
    McGreivy, Jesse
    Suzuki, Samuel
    Zhu, Min
    McCaffery, Ian
    Loh, Elwyn
    Gansert, Jennifer L.
    Kaufman, Peter A.
    [J]. LANCET ONCOLOGY, 2013, 14 (03): : 228 - 235
  • [3] Cost-utility analysis of fulvestrant versus exemestane in the second line treatment of postmenopausal women with advanced breast cancer
    Ryan, J
    Hirsch, M
    Knight, H
    [J]. VALUE IN HEALTH, 2004, 7 (06) : 670 - 670
  • [4] Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer
    Lustberg, Maryam B.
    Povoski, Stephen P.
    Zhao, Weiqiang
    Ziegler, Rebecca M.
    Sugimoto, Yasuro
    Ruppert, Amy S.
    Lehman, Amy M.
    Shiels, Donna R.
    Mrozek, Ewa
    Ramaswamy, Bhuvaneswari
    Layman, Rachel M.
    Brueggemeier, Robert W.
    Shapiro, Charles L.
    [J]. CLINICAL BREAST CANCER, 2011, 11 (04) : 221 - 227
  • [5] Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer
    Oakman, Catherine
    Moretti, Erica
    Santarpia, Libero
    Di Leo, Angelo
    [J]. FUTURE ONCOLOGY, 2011, 7 (02) : 173 - 186
  • [6] Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib
    Dirix, Luc Yves
    Ignacio, Jorge
    Nag, Shona
    Bapsy, Poonamally
    Gomez, Henry
    Raghunadharao, Digumarti
    Paridaens, Robert
    Jones, Stephen
    Falcon, Silvia
    Carpentieri, Marina
    Abbattista, Antonello
    Lobelle, Jean-Pierre
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (08) : 1253 - 1259
  • [7] A cost utility analysis of fulvestrant versus exemestane in the second line treatment of postmenopausal women with advanced breast cancer in Greece (preliminary results)
    Pangali, M
    Christodoulopoulou, A
    Ardavanis, A
    Barbounis, V
    Galani, E
    Skarlos, D
    [J]. VALUE IN HEALTH, 2005, 8 (06) : A44 - A44
  • [8] Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer
    Wang, Jiayu
    Xu, Binghe
    Yuan, Peng
    Ma, Fei
    Li, Qing
    Zhang, Pin
    Cai, Ruigang
    Fan, Ying
    Luo, Yang
    Li, Qiao
    [J]. MEDICINE, 2015, 94 (26)
  • [9] Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
    Lim, Bora
    Potter, David A.
    Salkeni, Mohamad A.
    Silverman, Paula
    Haddad, Tufia C.
    Forget, Frederic
    Awada, Ahmad
    Canon, Jean-Luc
    Danso, Michael
    Lortholary, Alain
    Bourgeois, Hugues
    Tan-Chiu, Elizabeth
    Vincent, Sylvie
    Bahamon, Brittany
    Galinsky, Kevin J.
    Patel, Chirag
    Neuwirth, Rachel
    Leonard, E. Jane
    Diamond, Jennifer R.
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (12) : 3329 - 3338
  • [10] Phase II trial of goserelin and exemestane combination therapy in premenopausal women with locally advanced or metastatic breast cancer.
    Wang, Jiayu
    Xu, Binghe
    Yuan, Peng
    Ma, Fei
    Li, Qing
    Zhang, Pin
    Luo, Yang
    Cai, Ruigang
    Fan, Ying
    Li, Qiao
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345